Avanos Medical, Inc. (NYSE:AVNS) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its stake in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 467.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 48,782 shares of the company's stock after acquiring an additional 40,186 shares during the period. Intech Investment Management LLC owned 0.11% of Avanos Medical worth $777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Avanos Medical during the 3rd quarter worth approximately $42,000. KBC Group NV boosted its stake in shares of Avanos Medical by 63.0% in the third quarter. KBC Group NV now owns 2,833 shares of the company's stock valued at $68,000 after buying an additional 1,095 shares in the last quarter. Atom Investors LP acquired a new position in Avanos Medical during the third quarter worth $210,000. EP Wealth Advisors LLC purchased a new position in Avanos Medical in the third quarter worth $212,000. Finally, US Bancorp DE lifted its holdings in Avanos Medical by 18.0% in the fourth quarter. US Bancorp DE now owns 14,093 shares of the company's stock valued at $224,000 after acquiring an additional 2,147 shares during the period. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Price Performance

Avanos Medical stock traded up $0.16 during mid-day trading on Thursday, reaching $14.32. The company had a trading volume of 353,569 shares, compared to its average volume of 295,990. The stock's 50-day simple moving average is $15.73 and its 200-day simple moving average is $18.48. Avanos Medical, Inc. has a 1 year low of $14.02 and a 1 year high of $25.36. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The company has a market capitalization of $658.62 million, a P/E ratio of 42.11 and a beta of 1.17.

Remove Ads

Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.03. The business had revenue of $179.60 million for the quarter, compared to analysts' expectations of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. On average, equities analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Insider Activity

In related news, SVP Kerr Holbrook sold 7,000 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares of the company's stock, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.90% of the company's stock.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.